Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anne Fuhlbrigge

Concepts (426)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Asthma
94
2023
2029
9.440
 Why?
Adrenal Cortex Hormones
26
2023
497
3.200
 Why?
Anti-Asthmatic Agents
26
2022
349
3.030
 Why?
Forced Expiratory Volume
19
2019
475
1.670
 Why?
Pulmonary Disease, Chronic Obstructive
11
2022
913
1.520
 Why?
Severity of Illness Index
20
2020
2537
1.090
 Why?
Anti-Inflammatory Agents
10
2016
447
0.960
 Why?
Lung Transplantation
10
2017
246
0.950
 Why?
Administration, Inhalation
23
2022
641
0.910
 Why?
Albuterol
5
2015
102
0.890
 Why?
Bronchodilator Agents
12
2016
239
0.860
 Why?
Budesonide
14
2016
87
0.840
 Why?
Humans
123
2023
114654
0.780
 Why?
Self Report
3
2023
696
0.780
 Why?
Nedocromil
11
2016
32
0.770
 Why?
Nasal Polyps
1
2021
49
0.750
 Why?
Pharmacogenetics
2
2015
149
0.730
 Why?
Endpoint Determination
2
2020
68
0.730
 Why?
Sinusitis
1
2021
174
0.660
 Why?
Lung
7
2019
3559
0.660
 Why?
Hospitalization
13
2020
1750
0.660
 Why?
Physicians
2
2021
772
0.640
 Why?
Virus Diseases
1
2021
195
0.640
 Why?
Sleep Apnea, Obstructive
1
2021
195
0.620
 Why?
Glucocorticoids
4
2022
532
0.620
 Why?
Food Hypersensitivity
1
2022
251
0.600
 Why?
Symptom Assessment
1
2019
119
0.600
 Why?
Child
53
2022
18407
0.590
 Why?
Disease Progression
14
2020
2380
0.570
 Why?
Oxygen Inhalation Therapy
4
2020
129
0.560
 Why?
Emergency Service, Hospital
9
2013
1815
0.560
 Why?
Male
79
2020
55579
0.560
 Why?
Bone Density
2
2014
432
0.550
 Why?
Androstadienes
3
2012
97
0.540
 Why?
Adult
44
2023
30542
0.540
 Why?
Patient Reported Outcome Measures
1
2018
250
0.540
 Why?
Precision Medicine
1
2020
337
0.530
 Why?
Female
78
2020
59488
0.520
 Why?
Managed Care Programs
8
2008
133
0.520
 Why?
Practice Patterns, Physicians'
7
2020
1177
0.490
 Why?
Cost Savings
1
2015
74
0.480
 Why?
Adrenergic beta-2 Receptor Agonists
4
2020
32
0.480
 Why?
Middle Aged
37
2020
26732
0.450
 Why?
Cost-Benefit Analysis
7
2022
544
0.440
 Why?
Peak Expiratory Flow Rate
2
2011
33
0.430
 Why?
Comorbidity
4
2021
1448
0.400
 Why?
Adolescent
36
2019
17837
0.390
 Why?
Surveys and Questionnaires
13
2022
4622
0.380
 Why?
Mentors
1
2012
156
0.370
 Why?
Remote Consultation
2
2022
42
0.370
 Why?
Child, Preschool
31
2016
9111
0.370
 Why?
Administration, Oral
6
2021
728
0.360
 Why?
United States
22
2022
12179
0.360
 Why?
Medical Records Systems, Computerized
3
2008
88
0.360
 Why?
Respiratory Function Tests
10
2015
522
0.350
 Why?
Faculty, Medical
1
2012
228
0.350
 Why?
Medication Adherence
3
2023
536
0.340
 Why?
Child Development
1
2014
385
0.340
 Why?
Aged
22
2022
19068
0.340
 Why?
Interprofessional Relations
3
2021
249
0.340
 Why?
Treatment Outcome
15
2017
9087
0.330
 Why?
Spirometry
8
2020
224
0.330
 Why?
Oxygen
3
2018
854
0.320
 Why?
Group Practice
1
2008
7
0.310
 Why?
Computer Simulation
1
2012
872
0.310
 Why?
Anti-Allergic Agents
2
2008
41
0.300
 Why?
Phenotype
5
2021
2796
0.300
 Why?
Quality of Life
11
2023
2353
0.300
 Why?
Dyspnea
3
2022
211
0.290
 Why?
Follow-Up Studies
17
2017
4411
0.280
 Why?
Drug Utilization
4
2005
167
0.270
 Why?
Primary Graft Dysfunction
2
2017
30
0.260
 Why?
Randomized Controlled Trials as Topic
7
2020
1214
0.260
 Why?
Quality Assurance, Health Care
1
2008
311
0.260
 Why?
Genetic Testing
1
2008
379
0.250
 Why?
Bronchiolitis Obliterans
3
2017
66
0.250
 Why?
Respiratory Sounds
1
2006
110
0.250
 Why?
Gift Giving
1
2005
9
0.250
 Why?
Diagnostic Techniques, Respiratory System
1
2005
5
0.250
 Why?
Allergists
2
2022
19
0.250
 Why?
Delivery of Health Care
2
2021
833
0.250
 Why?
Leadership
2
2022
292
0.240
 Why?
Cohort Studies
14
2013
4895
0.240
 Why?
Retrospective Studies
17
2022
12544
0.240
 Why?
Antibodies, Monoclonal
2
2008
1262
0.230
 Why?
Time Factors
10
2020
6115
0.230
 Why?
Young Adult
11
2019
10465
0.220
 Why?
Massachusetts
5
2016
134
0.220
 Why?
Recurrence
5
2013
935
0.220
 Why?
Genetic Variation
1
2008
870
0.220
 Why?
Health Status
1
2008
722
0.210
 Why?
Predictive Value of Tests
9
2012
1796
0.210
 Why?
Steroids
8
2011
144
0.210
 Why?
Rhinitis, Allergic, Perennial
1
2003
23
0.210
 Why?
Prevalence
4
2022
2250
0.210
 Why?
Multicenter Studies as Topic
4
2018
249
0.210
 Why?
Biomarkers
3
2021
3408
0.200
 Why?
Beclomethasone
1
2022
25
0.200
 Why?
Academic Medical Centers
2
2022
410
0.190
 Why?
Models, Theoretical
4
2007
515
0.190
 Why?
Social Class
2
2022
204
0.190
 Why?
Patient Preference
1
2023
167
0.190
 Why?
Tiotropium Bromide
2
2018
18
0.190
 Why?
Nebulizers and Vaporizers
2
2020
78
0.190
 Why?
Desensitization, Immunologic
1
2022
117
0.180
 Why?
Risk Factors
12
2018
8631
0.180
 Why?
Churg-Strauss Syndrome
1
2020
17
0.180
 Why?
Bronchoconstriction
3
2011
26
0.180
 Why?
Physician-Patient Relations
2
2021
462
0.180
 Why?
Capacity Building
1
2021
51
0.180
 Why?
Granulomatosis with Polyangiitis
1
2020
41
0.180
 Why?
Pulmonologists
1
2020
16
0.180
 Why?
Air Pollution, Indoor
2
2002
108
0.170
 Why?
Muscarinic Antagonists
1
2020
25
0.170
 Why?
Practice Guidelines as Topic
5
2020
1394
0.170
 Why?
Agammaglobulinemia
1
2020
30
0.170
 Why?
Specialization
1
2021
115
0.170
 Why?
Exercise Test
1
2022
544
0.160
 Why?
Prognosis
8
2017
3327
0.160
 Why?
Treatment Adherence and Compliance
1
2019
18
0.160
 Why?
Primary Health Care
4
2021
1512
0.160
 Why?
Receptors, IgE
2
2009
40
0.160
 Why?
Vitamin D
2
2012
341
0.150
 Why?
Biological Products
1
2020
166
0.150
 Why?
Fossil Fuels
1
1997
8
0.150
 Why?
Allergens
1
2021
413
0.150
 Why?
Aged, 80 and over
6
2019
6345
0.140
 Why?
Drug Prescriptions
2
2011
239
0.140
 Why?
Alemtuzumab
1
2017
12
0.140
 Why?
Photopheresis
1
2017
9
0.140
 Why?
Hypersensitivity
1
2020
252
0.140
 Why?
Respiration
1
2017
180
0.140
 Why?
Emergency Medical Services
2
2007
590
0.140
 Why?
Respiration Disorders
1
1997
69
0.140
 Why?
Drug Combinations
3
2012
287
0.140
 Why?
Physicians, Primary Care
3
2021
222
0.140
 Why?
Drug Therapy, Combination
5
2020
951
0.130
 Why?
Immunomodulation
1
2017
84
0.130
 Why?
Statistics, Nonparametric
1
2017
385
0.130
 Why?
Patient Admission
1
2018
176
0.130
 Why?
Postoperative Complications
2
2017
2128
0.130
 Why?
Immunoglobulin G
1
2020
770
0.130
 Why?
Referral and Consultation
1
2021
632
0.130
 Why?
Breath Tests
2
2008
82
0.130
 Why?
Scopolamine Derivatives
1
2015
6
0.130
 Why?
Embolism, Fat
1
2015
10
0.130
 Why?
Longitudinal Studies
6
2017
2387
0.130
 Why?
Genomics
2
2018
635
0.130
 Why?
Tobacco Smoke Pollution
2
2010
217
0.130
 Why?
Cholinergic Antagonists
1
2015
27
0.130
 Why?
Transplants
1
2015
36
0.130
 Why?
National Heart, Lung, and Blood Institute (U.S.)
1
2015
93
0.130
 Why?
Overweight
2
2011
471
0.120
 Why?
Fluticasone-Salmeterol Drug Combination
2
2012
12
0.120
 Why?
Telemedicine
1
2023
662
0.120
 Why?
Carcinoma, Bronchogenic
1
2015
17
0.120
 Why?
Respiratory Tract Infections
2
2012
319
0.120
 Why?
Graft Rejection
2
2013
513
0.120
 Why?
Environmental Exposure
3
2006
372
0.120
 Why?
Quality Improvement
1
2022
950
0.120
 Why?
Ambulatory Care Information Systems
2
2005
5
0.110
 Why?
Guideline Adherence
3
2020
490
0.110
 Why?
Prednisolone
1
2014
75
0.110
 Why?
Risk
4
2015
812
0.110
 Why?
Education, Medical, Continuing
2
2005
117
0.110
 Why?
Antibodies, Monoclonal, Humanized
2
2008
663
0.110
 Why?
Forecasting
1
2015
330
0.110
 Why?
Peer Group
2
2012
201
0.110
 Why?
Bronchial Hyperreactivity
3
2010
95
0.110
 Why?
Medicare
2
2022
665
0.110
 Why?
Transplantation
1
2013
23
0.110
 Why?
Double-Blind Method
5
2010
1660
0.110
 Why?
Airway Obstruction
1
2015
168
0.110
 Why?
Office Visits
4
2011
79
0.110
 Why?
Insurance Claim Review
1
2013
67
0.110
 Why?
Research
1
2015
394
0.100
 Why?
Costs and Cost Analysis
1
2013
196
0.100
 Why?
Growth
1
2012
55
0.100
 Why?
Methacholine Chloride
3
2008
47
0.100
 Why?
Feedback
1
2012
144
0.100
 Why?
Metered Dose Inhalers
1
2012
14
0.100
 Why?
Logistic Models
5
2017
1840
0.100
 Why?
Cytomegalovirus Infections
2
2012
180
0.100
 Why?
Socioeconomic Factors
3
2022
1078
0.100
 Why?
Mycoses
1
2012
67
0.100
 Why?
Drug Dosage Calculations
1
2011
21
0.100
 Why?
Obesity
3
2015
2508
0.100
 Why?
Antifungal Agents
1
2012
128
0.100
 Why?
Body Height
1
2012
180
0.100
 Why?
Effect Modifier, Epidemiologic
1
2011
12
0.090
 Why?
Multivariate Analysis
7
2017
1430
0.090
 Why?
Professional Role
1
2012
149
0.090
 Why?
Morbidity
2
2022
280
0.090
 Why?
Medication Errors
1
2012
88
0.090
 Why?
Patient Readmission
1
2016
610
0.090
 Why?
Diagnostic Errors
1
2012
149
0.090
 Why?
Epidemiologic Studies
1
2011
57
0.090
 Why?
Mycobacterium
1
2012
103
0.090
 Why?
Pneumococcal Vaccines
1
2012
131
0.090
 Why?
Lung Diseases
1
2017
701
0.090
 Why?
Secondary Prevention
1
2012
222
0.090
 Why?
Program Development
1
2012
341
0.090
 Why?
Decision Support Techniques
2
2012
355
0.090
 Why?
Ambulatory Care
2
2011
478
0.090
 Why?
Drug Resistance
1
2011
158
0.090
 Why?
Incidence
5
2020
2312
0.090
 Why?
Vitamin D Deficiency
1
2012
158
0.090
 Why?
Probability
1
2011
289
0.090
 Why?
Algorithms
1
2017
1467
0.090
 Why?
Chi-Square Distribution
2
2017
493
0.090
 Why?
Cross-Sectional Studies
6
2010
4407
0.090
 Why?
Bronchial Provocation Tests
2
2008
51
0.090
 Why?
Fluticasone
2
2008
87
0.080
 Why?
Immunoglobulin E
2
2008
314
0.080
 Why?
Vital Capacity
4
2017
255
0.080
 Why?
Proportional Hazards Models
1
2012
1075
0.080
 Why?
Surgical Wound Infection
1
2012
248
0.080
 Why?
Health Knowledge, Attitudes, Practice
2
2012
1183
0.080
 Why?
Lectins, C-Type
1
2009
61
0.080
 Why?
Receptors, Corticotropin-Releasing Hormone
1
2009
32
0.080
 Why?
Pandemics
3
2022
1317
0.080
 Why?
Smoking
3
2017
1381
0.080
 Why?
Health Services
2
2007
103
0.080
 Why?
Acute Disease
1
2011
910
0.080
 Why?
Odds Ratio
4
2017
953
0.080
 Why?
Kaplan-Meier Estimate
3
2016
811
0.080
 Why?
Medication Therapy Management
1
2010
67
0.080
 Why?
Health Services Accessibility
2
2021
762
0.080
 Why?
Vitamin K Epoxide Reductases
1
2008
11
0.080
 Why?
Cytochrome P-450 CYP2C9
1
2008
17
0.080
 Why?
Interviews as Topic
1
2011
582
0.080
 Why?
Genetic Predisposition to Disease
1
2016
2085
0.080
 Why?
Eosinophil Cationic Protein
1
2008
9
0.080
 Why?
Program Evaluation
1
2012
822
0.080
 Why?
Mixed Function Oxygenases
1
2008
36
0.080
 Why?
Aryl Hydrocarbon Hydroxylases
1
2008
41
0.080
 Why?
Genetic Techniques
1
2008
58
0.080
 Why?
Trastuzumab
1
2008
89
0.070
 Why?
Quality-Adjusted Life Years
2
2006
101
0.070
 Why?
Exercise Tolerance
2
2022
213
0.070
 Why?
Markov Chains
2
2006
114
0.070
 Why?
Cost Sharing
1
2008
14
0.070
 Why?
Smoking Cessation
1
2012
374
0.070
 Why?
Insurance, Pharmaceutical Services
1
2008
23
0.070
 Why?
Databases, Factual
1
2012
1125
0.070
 Why?
Adrenergic beta-Agonists
1
2008
126
0.070
 Why?
Tomography, X-Ray Computed
1
2017
2285
0.070
 Why?
State Health Plans
1
2008
32
0.070
 Why?
Chronic Disease
3
2017
1578
0.070
 Why?
Lung Diseases, Interstitial
1
2013
508
0.070
 Why?
Reimbursement Mechanisms
1
2008
77
0.070
 Why?
Antibodies, Anti-Idiotypic
1
2007
53
0.070
 Why?
Warfarin
1
2008
135
0.070
 Why?
Mycobacterium Infections, Nontuberculous
1
2012
333
0.070
 Why?
Factor Analysis, Statistical
1
2008
257
0.070
 Why?
Omalizumab
1
2007
45
0.070
 Why?
Health Surveys
2
2006
443
0.070
 Why?
Antiviral Agents
1
2012
645
0.070
 Why?
Influenza Vaccines
1
2012
497
0.070
 Why?
Animals, Domestic
1
2006
11
0.070
 Why?
Biomedical Research
1
2012
585
0.070
 Why?
Receptor, ErbB-2
1
2008
300
0.070
 Why?
Eosinophils
1
2008
278
0.070
 Why?
Infant
3
2008
7959
0.060
 Why?
Physicians, Family
2
2004
201
0.060
 Why?
Body Mass Index
3
2015
1958
0.060
 Why?
Models, Biological
1
2012
1620
0.060
 Why?
Clinical Competence
1
2012
893
0.060
 Why?
Health Benefit Plans, Employee
1
2005
20
0.060
 Why?
Health Policy
1
2008
334
0.060
 Why?
Mass Screening
1
2012
1004
0.060
 Why?
Database Management Systems
1
2005
47
0.060
 Why?
Hip Fractures
1
2006
75
0.060
 Why?
Patients
1
2006
163
0.060
 Why?
Prenatal Exposure Delayed Effects
1
2010
452
0.060
 Why?
Insurance Coverage
1
2006
200
0.060
 Why?
Patient Education as Topic
3
2005
680
0.060
 Why?
Gene Expression Profiling
1
2011
1518
0.060
 Why?
Cost of Illness
2
2003
254
0.060
 Why?
Utilization Review
1
2004
34
0.060
 Why?
Anticoagulants
1
2008
550
0.060
 Why?
Sex Factors
3
2016
1715
0.060
 Why?
Anti-Bacterial Agents
2
2004
1481
0.060
 Why?
Vaccination
1
2012
1204
0.060
 Why?
Medicaid
1
2008
406
0.060
 Why?
Circadian Rhythm
1
2006
354
0.050
 Why?
Parents
3
2006
1186
0.050
 Why?
Clinical Trials as Topic
2
2005
931
0.050
 Why?
Nitric Oxide
1
2008
823
0.050
 Why?
Attitude to Health
1
2006
406
0.050
 Why?
Choice Behavior
1
2004
155
0.050
 Why?
Case Management
1
2003
62
0.050
 Why?
Puerto Rico
1
2022
51
0.050
 Why?
Lung Neoplasms
1
2015
2177
0.050
 Why?
Symptom Flare Up
1
2022
38
0.050
 Why?
Sputum
1
2004
285
0.050
 Why?
Academies and Institutes
1
2022
44
0.050
 Why?
Minority Groups
1
2003
227
0.050
 Why?
Survival Rate
2
2016
1644
0.050
 Why?
Health Services Research
1
2004
371
0.050
 Why?
Clinical Trials, Phase II as Topic
1
2020
59
0.040
 Why?
Clinical Trials, Phase III as Topic
1
2020
82
0.040
 Why?
Electronics
1
2021
67
0.040
 Why?
Sample Size
1
2020
112
0.040
 Why?
Efficiency
1
2021
84
0.040
 Why?
Risk Assessment
3
2020
2968
0.040
 Why?
Schools, Medical
1
2021
120
0.040
 Why?
Health Care Reform
1
2021
92
0.040
 Why?
Stress, Psychological
1
2007
944
0.040
 Why?
Language
1
2022
263
0.040
 Why?
Pragmatic Clinical Trials as Topic
1
2020
47
0.040
 Why?
Patient Selection
2
2020
641
0.040
 Why?
Patient Compliance
2
2016
525
0.040
 Why?
Time
1
2019
70
0.040
 Why?
Cluster Analysis
2
2014
455
0.040
 Why?
Health Education
1
2002
323
0.040
 Why?
Quality of Health Care
1
2003
573
0.040
 Why?
Cooperative Behavior
1
2021
381
0.040
 Why?
Sensitivity and Specificity
3
2013
1691
0.040
 Why?
Republic of Korea
1
2017
27
0.040
 Why?
Poland
1
2017
29
0.040
 Why?
Bronchitis, Chronic
1
2017
17
0.040
 Why?
Patient-Centered Care
1
2003
473
0.040
 Why?
Antineoplastic Agents
1
2008
1879
0.040
 Why?
Nitrogen Dioxide
1
1997
20
0.040
 Why?
Pediatrics
1
2005
979
0.040
 Why?
Long-Term Care
1
2018
77
0.040
 Why?
Self Concept
1
2019
214
0.040
 Why?
Geography
1
2018
177
0.040
 Why?
Aftercare
1
2019
186
0.040
 Why?
Monitoring, Physiologic
2
2012
249
0.030
 Why?
Netherlands
1
2016
64
0.030
 Why?
Feasibility Studies
1
2020
740
0.030
 Why?
Tuberculosis, Pulmonary
1
2017
112
0.030
 Why?
Perception
1
2019
311
0.030
 Why?
Formoterol Fumarate
1
2015
7
0.030
 Why?
Forced Expiratory Flow Rates
1
2015
11
0.030
 Why?
Salmeterol Xinafoate
1
2015
41
0.030
 Why?
Ethanolamines
1
2015
19
0.030
 Why?
Immunosuppressive Agents
2
2015
646
0.030
 Why?
Receptors, Adrenergic, beta-2
1
2015
39
0.030
 Why?
Polymorphism, Single Nucleotide
2
2016
1879
0.030
 Why?
Self Efficacy
1
2019
355
0.030
 Why?
Dose-Response Relationship, Drug
2
2011
1842
0.030
 Why?
Treatment Failure
1
2016
331
0.030
 Why?
Postoperative Period
1
2016
289
0.030
 Why?
Age Factors
3
2008
2894
0.030
 Why?
Pilot Projects
1
2020
1373
0.030
 Why?
Education
1
2015
95
0.030
 Why?
Patient Acceptance of Health Care
1
2021
681
0.030
 Why?
Fatal Outcome
1
2015
284
0.030
 Why?
Biopsy
2
2013
1036
0.030
 Why?
Combined Modality Therapy
1
2017
1121
0.030
 Why?
Gene Expression
1
2018
1421
0.030
 Why?
Tissue Donors
1
2015
316
0.030
 Why?
Telephone
2
2005
152
0.030
 Why?
Extracorporeal Membrane Oxygenation
1
2015
241
0.030
 Why?
Lipopeptides
1
2012
14
0.030
 Why?
Echinocandins
1
2012
8
0.030
 Why?
Hypoxia
1
2019
957
0.030
 Why?
Intention to Treat Analysis
1
2012
68
0.030
 Why?
Amphotericin B
1
2012
29
0.030
 Why?
Aspergillosis
1
2012
23
0.030
 Why?
Candidiasis
1
2012
51
0.030
 Why?
Transplantation, Homologous
1
2013
377
0.020
 Why?
Age Distribution
2
2003
342
0.020
 Why?
Mycobacterium avium Complex
1
2012
92
0.020
 Why?
Triazoles
1
2012
131
0.020
 Why?
Cromolyn Sodium
2
2001
13
0.020
 Why?
Colorado
1
2021
4099
0.020
 Why?
Self Care
2
2005
349
0.020
 Why?
Leukotriene Antagonists
1
2011
41
0.020
 Why?
Reference Values
1
2012
743
0.020
 Why?
Functional Residual Capacity
1
2010
7
0.020
 Why?
Genome-Wide Association Study
1
2016
1177
0.020
 Why?
Costa Rica
1
2010
16
0.020
 Why?
Principal Component Analysis
1
2011
175
0.020
 Why?
Health
1
2010
74
0.020
 Why?
Nontuberculous Mycobacteria
1
2012
204
0.020
 Why?
Inhalation
1
2010
26
0.020
 Why?
Prospective Studies
2
2012
6217
0.020
 Why?
Environment
1
2011
332
0.020
 Why?
Observation
1
2008
50
0.020
 Why?
Sex Ratio
1
2008
14
0.020
 Why?
Least-Squares Analysis
1
2008
70
0.020
 Why?
Models, Econometric
1
2008
34
0.020
 Why?
Health Services Administration
1
2007
7
0.020
 Why?
Social Isolation
1
2007
52
0.020
 Why?
Treatment Refusal
1
2008
85
0.020
 Why?
Puberty
1
2008
135
0.020
 Why?
Intelligence
1
2007
130
0.020
 Why?
Body Weight
1
2011
870
0.020
 Why?
Exercise
1
2016
1644
0.020
 Why?
Child Behavior Disorders
1
2007
131
0.020
 Why?
Animals
1
2006
31698
0.020
 Why?
CD4-Positive T-Lymphocytes
1
2011
959
0.020
 Why?
Insurance, Health
1
2007
244
0.020
 Why?
Genotype
1
2009
1760
0.010
 Why?
Bronchoconstrictor Agents
1
2003
14
0.010
 Why?
Case-Control Studies
1
2010
3003
0.010
 Why?
Health Status Indicators
1
2004
156
0.010
 Why?
Organizational Innovation
1
2004
132
0.010
 Why?
Systems Integration
1
2003
37
0.010
 Why?
Motor Activity
1
2007
640
0.010
 Why?
Computer Systems
1
2003
45
0.010
 Why?
Child Welfare
1
2004
192
0.010
 Why?
Self Disclosure
1
2002
59
0.010
 Why?
Histamine H1 Antagonists
1
2002
28
0.010
 Why?
Drug Administration Schedule
1
2004
718
0.010
 Why?
Administration, Intranasal
1
2002
75
0.010
 Why?
Nurse's Role
1
2003
106
0.010
 Why?
Point-of-Care Systems
1
2003
136
0.010
 Why?
Confidence Intervals
1
2002
305
0.010
 Why?
Regression Analysis
1
2003
944
0.010
 Why?
Caregivers
1
2007
717
0.010
 Why?
Health Care Surveys
1
2002
539
0.010
 Why?
Decision Support Systems, Clinical
1
2003
176
0.010
 Why?
Sex Distribution
1
2001
337
0.010
 Why?
Patient Satisfaction
1
2004
578
0.010
 Why?
Disease Management
1
2003
560
0.010
 Why?
Linear Models
1
2002
768
0.010
 Why?
Pregnancy
1
2010
5517
0.010
 Why?
Internet
1
2003
596
0.010
 Why?
Bronchoscopy
1
2000
245
0.010
 Why?
Survival Analysis
1
2000
1211
0.010
 Why?
Infant, Newborn
1
2004
5044
0.010
 Why?
Fuhlbrigge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (426) concept(s)
_
Co-Authors Expand Description
See all (17) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)